{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:33:15Z","timestamp":1786545195944,"version":"build-2736575974"},"reference-count":65,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T00:00:00Z","timestamp":1603584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Ministerie van Volksgezondheid, Welzijn en Sport","doi-asserted-by":"publisher","award":["no grant"],"award-info":[{"award-number":["no grant"]}],"id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Neisseria meningitidis is often asymptomatically carried in the nasopharynx but may cause invasive meningococcal disease, leading to morbidity and mortality. Meningococcal conjugate vaccinations induce functional protective antibodies against capsular antigens, but seroprotection wanes over time. We measured functional antibody titers five years after administration of a single dose of the meningococcal ACWY-polysaccharide-specific tetanus toxoid-conjugated (MenACWY-TT) vaccine in adolescents and middle-aged adults in the Netherlands, using the serum bactericidal antibody with baby rabbit complement (rSBA) assay. Protection was defined as rSBA titer \u22658. The meningococcal ACWY-specific serum IgG concentrations were measured with a multiplex immunoassay. Duration of protection was estimated by a bi-exponential decay model. Sufficient protection for MenC, MenW, and MenY was achieved in 94\u201396% of the adolescents five years postvaccination, but, in middle-aged adults, only in 32% for MenC, 65% for MenW and 71% for MenY. Median duration of protection for MenCWY was 4, 14, and 21 years, respectively, in middle-aged adults, while, in adolescents, it was 32, 98, and 33 years. Our findings suggest that adolescents, primed in early childhood with MenC conjugate vaccination, remain sufficiently protected after a single dose of MenACWY-TT vaccine. Middle-aged adults without priming vaccination show fast waning of antibodies, particularly MenC, for which protection is lost after four years.<\/jats:p>","DOI":"10.3390\/vaccines8040624","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T02:34:54Z","timestamp":1603679694000},"page":"624","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Different Long-Term Duration of Seroprotection against Neisseria meningitidis in Adolescents and Middle-Aged Adults after a Single Meningococcal ACWY Conjugate Vaccination in The Netherlands"],"prefix":"10.3390","volume":"8","author":[{"given":"Milou","family":"Ohm","sequence":"first","affiliation":[{"name":"Centre for Infectious Disease Control (Cib), National Institute of Public Health and the Environment (RIVM), 3720 BA Bilthoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie M.","family":"van Rooijen","sequence":"additional","affiliation":[{"name":"Centre for Infectious Disease Control (Cib), National Institute of Public Health and the Environment (RIVM), 3720 BA Bilthoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel A.","family":"Bona\u010di\u0107 Marinovi\u0107","sequence":"additional","affiliation":[{"name":"Centre for Infectious Disease Control (Cib), National Institute of Public Health and the Environment (RIVM), 3720 BA Bilthoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00ebtte B.","family":"van Ravenhorst","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Amsterdam UMC, 1007 MB Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-9895","authenticated-orcid":false,"given":"Marieke","family":"van der Heiden","sequence":"additional","affiliation":[{"name":"Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, 114 18 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Buisman","sequence":"additional","affiliation":[{"name":"Centre for Infectious Disease Control (Cib), National Institute of Public Health and the Environment (RIVM), 3720 BA Bilthoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth A.M.","family":"Sanders","sequence":"additional","affiliation":[{"name":"Centre for Infectious Disease Control (Cib), National Institute of Public Health and the Environment (RIVM), 3720 BA Bilthoven, The Netherlands"},{"name":"Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children\u2019s Hospital, University Medical Center, 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy A.M.","family":"Berbers","sequence":"additional","affiliation":[{"name":"Centre for Infectious Disease Control (Cib), National Institute of Public Health and the Environment (RIVM), 3720 BA Bilthoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Brandtzaeg, P. (2006). Pathogenesis and Pathophysiology of Invasive Meningococcal. Handb. Meningococcal Dis., 427.","DOI":"10.1002\/3527608508.ch21"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal Disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N. Eng. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1473-3099(10)70048-7","article-title":"Global and regional risk of disabling sequelae from bacterial meningitis: A systematic review and meta-analysis","volume":"10","author":"Edmond","year":"2010","journal-title":"Lancet. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.4049\/jimmunol.1200451","article-title":"B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: Little association with serum IgG antibody","volume":"189","author":"Perrett","year":"2012","journal-title":"J. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lewis, L., and Ram, S. (2013). Meningococcal disease and the complement system. Virulence, 5.","DOI":"10.4161\/viru.26515"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1016\/j.vaccine.2015.07.019","article-title":"Serum bactericidal antibody assays\u2014The role of complement in infection and immunity","volume":"33","author":"McIntosh","year":"2015","journal-title":"Vaccine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.4161\/hv.20473","article-title":"Importance of circulating antibodies in protection against meningococcal disease","volume":"8","author":"Erlich","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1542\/peds.2008-3645","article-title":"Booster vaccinations: Can immunologic memory outpace disease pathogenesis?","volume":"124","author":"Pichichero","year":"2009","journal-title":"Pediatrics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.inf.0000195594.41449.c6","article-title":"Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in The Netherlands","volume":"25","author":"Spanjaard","year":"2006","journal-title":"Pediatric Infect. Dis. J."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"De Voer, R.M., Mollema, L., Schepp, R.M., de Greeff, S.C., van Gageldonk, P.G., de Melker, H.E., Sanders, E.A., Berbers, G.A., and van der Klis, F.R. (2010). Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal C conjugate vaccine. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012144"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Stoof, S.P., van der Klis, F.R., van Rooijen, D.M., Knol, M.J., Sanders, E.A., and Berbers, G.A. (2014). Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100651"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1016\/j.vaccine.2017.06.007","article-title":"Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination","volume":"35","author":"Sanders","year":"2017","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: A systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/erv.09.48","article-title":"Meningococcal vaccines and herd immunity: Lessons learned from serogroup C conjugate vaccination programs","volume":"8","author":"Trotter","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"ref_17","unstructured":"De Melker, H.E., and Schurink-van \u2018t Klooster, T.M. (2019). The National Immunisation Programme in The Netherlands: Surveillance and Developments in 2018\u20132019, National Institute for Public Health and the Environment, Ministry of Health, Welfare and Sport."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Van der Heiden, M., Boots, A.M.H., Bonacic Marinovic, A.A., de Rond, L.G.H., van Maurik, M., Tcherniaeva, I., Berbers, G.A.M., and Buisman, A.M. (2017). Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00817"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","article-title":"Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15\u201325 years","volume":"27","author":"Ostergaard","year":"2009","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1128\/CVI.00260-12","article-title":"Immunogenicity and safety of a meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with one dose of bivalent and quadrivalent meningococcal polysaccharide vaccines: A phase III, controlled, randomized, and modified blind-observer study","volume":"19","author":"Khalil","year":"2012","journal-title":"Clin. Vaccine Immunol. CVI"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/INF.0b013e3182054ab9","article-title":"Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age","volume":"30","author":"Baxter","year":"2011","journal-title":"Pediatric Infect. Dis. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4161\/hv.7.2.14068","article-title":"Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults","volume":"7","author":"Bermal","year":"2011","journal-title":"Hum. Vaccines"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Borja-Tabora, C., Montalban, C., Memish, Z.A., Van der Wielen, M., Bianco, V., Boutriau, D., and Miller, J. (2013). Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: Results of an open, randomised, controlled study. BMC Infect. Dis., 13.","DOI":"10.1186\/1471-2334-13-116"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40266-013-0065-0","article-title":"Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: Results of an open-label, randomized, controlled trial","volume":"30","author":"Dbaibo","year":"2013","journal-title":"Drugs Aging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.exger.2017.12.014","article-title":"Lower antibody functionality in middle-aged adults compared to adolescents after primary meningococcal vaccination: Role of IgM","volume":"105","author":"Bogaard","year":"2018","journal-title":"Exp. Gerontol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Borja-Tabora, C.F., Montalban, C., Memish, Z.A., Boutriau, D., Kolhe, D., Miller, J.M., and Van der Wielen, M. (2015). Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-1138-y"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Borja-Tabora, C.F.C., Peyrani, P., Webber, C., Van der Wielen, M., Cheuvart, B., De Schrevel, N., Bianco, V., Aris, E., Cutler, M., and Li, P. (2020). A phase 2b\/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55\u2009years. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-05104-5"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Baxter, R., Keshavan, P., Welsch, J.A., Han, L., and Smolenov, I. (2016). Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants. Hum. Vaccines Immunother.","DOI":"10.1080\/21645515.2015.1136040"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1016\/j.vaccine.2017.06.053","article-title":"Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial","volume":"35","author":"Knol","year":"2017","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection--serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"ref_33","first-page":"780","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1128\/CVI.00364-08","article-title":"Simultaneous detection of Haemophilus influenzae type b polysaccharide-specific antibodies and Neisseria meningitidis serogroup A, C, Y, and W-135 polysaccharide-specific antibodies in a fluorescent-bead-based multiplex immunoassay","volume":"16","author":"Schepp","year":"2009","journal-title":"Clin. Vaccine Immunol. CVI"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1128\/CVI.00478-07","article-title":"Development of a fluorescent-bead-based multiplex immunoassay to determine immunoglobulin G subclass responses to Neisseria meningitidis serogroup A and C polysaccharides","volume":"15","author":"Engels","year":"2008","journal-title":"Clin. Vaccine Immunol. CVI"},{"key":"ref_36","first-page":"272","article-title":"Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135","volume":"11","author":"Lal","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1016\/j.vaccine.2007.07.019","article-title":"Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005","volume":"25","author":"Ceyhan","year":"2007","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJM197709292971302","article-title":"Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age","volume":"297","author":"Peltola","year":"1977","journal-title":"N. Eng. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0022-3476(96)70389-X","article-title":"Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children","volume":"128","author":"King","year":"1996","journal-title":"J. Pediatrics"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1745-6673-8-4","article-title":"Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine","volume":"8","author":"Elias","year":"2013","journal-title":"J. Occup. Med. Toxicol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.vaccine.2019.03.045","article-title":"Kinetics of maternally-derived serogroup A, C, Y and W-specific meningococcal immunoglobulin G in Malian women and infants","volume":"37","author":"Findlow","year":"2019","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"van Ravenhorst, M.B., Marinovic, A.B., van der Klis, F.R., van Rooijen, D.M., van Maurik, M., Stoof, S.P., Sanders, E.A., and Berbers, G.A. (2016). Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination. Vaccine.","DOI":"10.1016\/j.vaccine.2016.10.049"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.epidem.2014.08.002","article-title":"A two-phase within-host model for immune response and its application to serological profiles of pertussis","volume":"9","author":"Kretzschmar","year":"2014","journal-title":"Epidemics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1016\/j.vaccine.2013.05.073","article-title":"A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens","volume":"31","author":"Berbers","year":"2013","journal-title":"Vaccine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.epidem.2016.04.001","article-title":"Linking the seroresponse to infection to within-host heterogeneity in antibody production","volume":"16","author":"Teunis","year":"2016","journal-title":"Epidemics"},{"key":"ref_46","unstructured":"Plummer, M. (2003, January 20\u201322). JAGS: A program for analysis of Bayesian graphial models using Gibbs sampling. Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003), Vienna, Austria."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1002\/(SICI)1097-0258(19981130)17:22<2635::AID-SIM954>3.0.CO;2-C","article-title":"Improved confidence intervals for the difference between binomial proportions based on paired data","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1097\/INF.0b013e31823e1e34","article-title":"A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers","volume":"31","author":"McVernon","year":"2012","journal-title":"Pediatric Infect. Dis. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12325-013-0032-5","article-title":"Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT","volume":"30","author":"Findlow","year":"2013","journal-title":"Adv. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.ijid.2012.10.001","article-title":"Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT)","volume":"17","author":"Bianco","year":"2013","journal-title":"Int. J. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1097\/INF.0000000000000866","article-title":"Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial","volume":"34","author":"Baxter","year":"2015","journal-title":"Pediatric Infect. Dis. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/INF.0000000000001123","article-title":"Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children","volume":"35","author":"Klein","year":"2016","journal-title":"Pediatric Infect. Dis. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.4161\/hv.29571","article-title":"Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia","volume":"10","author":"Ilyina","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijid.2015.07.003","article-title":"Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years","volume":"38","author":"Lalwani","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1128\/CVI.00207-09","article-title":"Quadrivalent meningococcal vaccination of adults: Phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra","volume":"16","author":"Reisinger","year":"2009","journal-title":"Clin. Vaccine Immunol. CVI"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/cei.13202","article-title":"Immunogenicity of meningococcal polysaccharide ACWY vaccine in primary immunized or revaccinated adults","volume":"194","author":"Ferlito","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nri2508","article-title":"B-cell responses to vaccination at the extremes of age","volume":"9","author":"Siegrist","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1016\/j.vaccine.2020.04.067","article-title":"Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in \u226556-year-olds: A Phase III randomized study","volume":"38","author":"Koehler","year":"2020","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1086\/529197","article-title":"Biology of immune responses to vaccines in elderly persons","volume":"46","author":"Weinberger","year":"2008","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/cid\/civ506","article-title":"Disease Burden of Invasive Meningococcal Disease in the Netherlands Between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex","volume":"61","author":"Stoof","year":"2015","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciu601","article-title":"A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination","volume":"59","author":"Bijlsma","year":"2014","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_62","unstructured":"(2020, September 23). Nimenrix\u2014Assessment Report\u2014Procedure, No. EMEA\/H\/C\/002226. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/nimenrix-epar-public-assessment-report_en.pdf."},{"key":"ref_63","first-page":"1808","article-title":"Factors contributing to the immunogenicity of meningococcal conjugate vaccines","volume":"12","author":"Berti","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1473-3099(14)70806-0","article-title":"Epidemiology of invasive meningococcal disease in the Netherlands, 1960\u20132012: An analysis of national surveillance data","volume":"14","author":"Bijlsma","year":"2014","journal-title":"Lancet. Infect. Dis."},{"key":"ref_65","unstructured":"Knol, M.J., de Melker, H.E., Berbers, G.A.M., van Ravenhorst, M.B., Ruijs, W.L.M., van Vliet, J.A., Kemmeren, J.M., Suijkerbuijk, A., van Lier, E.A., and Sanders, E.A.M. (2017). Meningococcal Disease in The Netherlands. Background Information for the Health Council, National Institute for Public Health and the Environment."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/624\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:27:51Z","timestamp":1760178471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,25]]},"references-count":65,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["vaccines8040624"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8040624","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,25]]}}}